파나마 - 영어 - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios richet s.a. - tigeciclina - tigeciclina....50.0 mg

파나마 - 영어 - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios normon, s.a. - tigeciclina - tigeciclina....50,00 mg

파나마 - 영어 - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios stein, s.a. - tigeciclina - tigeciclina....50.00 mg

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tigecycline, quantity: 50 mg - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; lactose monohydrate - tygacil is indicated for the treatment of the following infections in adults: - complicated skin and skin structure infections, including those with methicillin-resistant staphylococcus aureus (mrsa), where there is suspected or proven resistance to, or intolerance of, or there are co-morbidities preventing its use of, other available agents. complicated intra-abdominal infections, where there is suspected or proven resistance to, or intolerance of, or there are co-morbidities preventing its use of, other available agents.

이스라엘 - 영어 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tigecycline - powder for solution for infusion - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, clostridium perfringens, and peptostreptococcus micros.community-acquired bacterial pneumonia:community-acquired bacterial pneumonia caused by streptococcus pneumoniae (penicillin susceptible isolates), including cases with concurrent bacteremia, haemophilus influenzae (beta-lactamase negative isolates), and legionella pneumophila.

미국 - 영어 - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - tigecycline (unii: 70je2n95kr) (tigecycline - unii:70je2n95kr) - tigecycline 50 mg in 5 ml - tygacil is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus ), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis. tygacil is indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections caused by susceptible isolates of citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus ), bacteroides f

이스라엘 - 영어 - Ministry of Health

pfizer pharmaceuticals israel ltd - tigecycline - lyophilized powder for infusion - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

필리핀 - 영어 - FDA (Food And Drug Administration)

n/a; importer: sun pharma philippines, inc.; distributor: n/a - tigecycline - lyophilized powder for injection (iv infusion) - 50 mg

몰타 - 영어 - Medicines Authority

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - tigecycline - powder for solution for infusion - tigecycline 50 mg - antibacterials for systemic use

싱가포르 - 영어 - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - tigecycline - injection, powder, lyophilized, for solution - tigecycline 50.0 mg